BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
BioVie announced full enrollment of its ADDRESS-LC Phase 2 trial evaluating bezisterim for neurological symptoms of Long COVID. The study, which enrolled approximately 200 patients, is fully funded by a $13.13 million grant from the U.S. Department of War (formerly Department of Defense).
Key figures
- Drug Name
- bezisterim
- Phase Of Trial
- Phase 2
- Dosage
- 20 mg oral capsule twice daily
- Grant amount
- $13.13 million
- Enrollment count
- 200
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.